Human Genome Sciences Completes Enrollment in Albuferon Trial
Human Genome Sciences has started dosing in ACHIEVE 2/3, the second of two Phase III trials of Albuferon in combination with ribavirin in treatment-naive patients with chronic hepatitis C.
The two randomized, open-label, active-controlled, multicenter, noninferiority trials, ACHIEVE 1 and ACHIEVE 2/3, will evaluate the efficacy, safety and quality of life of Albuferon (albinterferon alfa-2b) in combination with ribavirin versus Pegasys (peginterferon alfa-2a) in combination with ribavirin.
ACHIEVE 2/3 enrolled 933 patients with genotypes 2 and 3 chronic hepatitis C. ACHIEVE 1 completed enrollment of 1,331 treatment-naive patients with genotype 1 chronic hepatitis C in August, Human Genome Sciences said.
Higher doses of monthly Albuferon in combination with ribavirin will be explored in a separate Phase IIb trial conducted by Human Genome Sciences’ partner Novartis.